Genocea Biosciences Inc Price/Sales
What is the Price/Sales of Genocea Biosciences Inc?
The Price/Sales of Genocea Biosciences Inc is 0.07
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Genocea Biosciences Inc
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Companies with price/sales similar to Genocea Biosciences Inc
- CESC has Price/Sales of 0.07
- Pivot Technology Solutions has Price/Sales of 0.07
- Flexituff Ventures International has Price/Sales of 0.07
- Dorel Industries has Price/Sales of 0.07
- Conduity Capital Plc has Price/Sales of 0.07
- UniVision Engineering has Price/Sales of 0.07
- Genocea Biosciences Inc has Price/Sales of 0.07
- North Asia Strategic has Price/Sales of 0.07
- Redsun Properties has Price/Sales of 0.07
- United Natural Foods has Price/Sales of 0.07
- Vintana Plc has Price/Sales of 0.07
- Wai Chun Bio-Technology has Price/Sales of 0.07
- Farm Pride Foods has Price/Sales of 0.07